AngioDynamics, Inc. (AngioDynamics) has appointed Jan Keltjens as president and chief executive officer (CEO) of the company, effective March 1, 2009. As president and CEO, Keltjens, will succeed Eamonn Hobbs, who has led the company for the past 21 years and will become vice chairman of the board of directors. Keltjens comes to AngioDynamics after serving as president and CEO of CryoCath Technologies, Inc. since early 2007. Keltjens previously served in various leadership positions at Cordis.
Keltjens previously served in various leadership positions, including his last position as Worldwide general manager of Cordis Neurovascular. He first joined Cordis in 1995 as vice president and managing director responsible for international manufacturing and distribution operations, as well as research and development. He was promoted to vice president of european marketing and vice president of worldwide strategic marketing for Cordis Cardiology. Before joining Cordis, Keltjens led research and development departments at Unilever and was managing director of a group of small high tech companies.
“Jan’s appointment is the culmination of an extensive search for the best candidate to build on the successes of Eamonn’s founding leadership and take us to the next level in the Company’s growth and development,” said AngioDynamics’ chairman of the board of directors, Vincent Bucci. “Eamonn built AngioDynamics into a $200-million enterprise, and we believe Jan is the right person to take us to the half billion dollar revenue level and beyond. Jan brings to the Company extensive global operating and managerial experience, as well as very strong industry background and a continuous track record of success. The entire Board of Directors joins me in welcoming Jan to the Company, and we look forward to working with him.”
“AngioDynamics is a very successful company and I look forward to working with Eamonn, the Board, and the entire team during the transition,” said. Keltjens. “The Company’s IRE technology has the potential to become a game-changing technology addressing significant unmet clinical needs in the oncology field, and I believe there are many more opportunities to consistently grow the Access, Peripheral Vascular and Oncology businesses. At the same time, a strong balance sheet presents more opportunities for growth through carefully targeted and well executed acquisitions. ”
“Jan Keltjens brings to our Company a comprehensive understanding of our current markets and during his career has even managed an angiographic catheter product line. I look forward to working with Jan on a smooth transition of the CEO’s responsibilities, as well as refining my ongoing role with the Company in the development of markets for IRE technology,” said Hobbs.
Keltjens was born and raised in The Netherlands. He holds a masters degree in physics, with a specialty in low-temperature physics from the University of Eindhoven.